Life Science Nation invites all eligible early stage life science companies to apply to Innovation Challenge to showcase their technologies.
Companies from all categories of life science are encouraged to apply to Innovation Challenge for RESI Healthtech Week. Eligible companies can apply to Day 1, the First Coast Innovator’s Gathering, Day 2 RESI Global Partnering or both. Applicants will have the opportunity for excellent visibility among investors and strategic partners.
For the first time this fall, Life Science Nation will have two days of Innovation Challenge competition as part of the RESI Healthtech Week (September 5-7, 2018). The Innovation Challenge offers selected companies the chance to gain more visibility from the early-stage investors in attendance.
Day 2 Redefining Early Stage Investments
All early-stage life science companies are eligible to apply. Finalists will be highlighted in multiple outlets:
Your country and technology highlighted at the conference
All conference attendees will have the chance to “invest” RESI Cash in their favorite technologies
LSN Newsletter Announcement to a readership of 20,000+
Featured on RESI Conference website Featured in the printed and online program guide
Winners will be announced during the cocktail reception
It is FREE to apply, click here.
Day 1, First Coast Innovation Challenge
All early-stage life science companies from DC through Boston are eligible to apply. Applicants will be highlighted in multiple outlets:
10 finalists will be selected to pitch to a panel of investors
Applicants present a poster of their technology
All featured in the printed and online program guide
Attendees have access to partnering platform
Attendees have access to early-stage investor panels
Attendance on Day 1 for companies is $300, click here.
9 Hamilton Place, Suite 2B, Boston, MA 02108 +1 617-600-0668 | resi@lifesciencenation.com
The first half of 2018 has brought to the surface many debated topics not only for the United States but also the world—universal healthcare, innovation, and leadership. This year, headlines continue to arise almost daily detailing reforms to the healthcare system, while other countries continue to make advances in their universal healthcare programs. One of the biggest corporations in the world, Amazon, is accelerating their involvement in the healthcare industry with big-name partnerships, leadership appointments, and strategic acquisitions. They’ve also recently purchased office space in Boston, MA, one of the biggest life science hubs in the world—where Life Science Nation (LSN) began its focus on helping early-stage life science companies seeking capital.
The urgency in healthcare.
Life Science Nation was founded with the intention to move life science innovation forward for a real impact on the global development of healthcare, which has only become more urgent. Throughout LSN’s experience supporting life science companies, lack of access to capital is holding back the advancement of many life science companies. LSN dedicates itself to helping early-stage companies navigate the funding ‘Valley of Death’, which is why LSN created a new three-day event called RESI Healthtech Week. Today, LSN will discuss the benefit of attending Day 1, the First Coast Innovator’s Gathering, for tech hubs across the northeast with technologies or companies looking to change the future of healthcare.
What is the First Coast?
The First Coast, as LSN has deemed it, is the location identified as the premier hub for life science innovation, similar to how Silicon Valley is viewed as the premier (and original) tech hub. Over the years the First, Second, and Third Coast have been identified as hubs across the country made up of different states including Houston and New York City. All have been vying to be central locations for massive innovation in the life sciences. However, Life Science Nation takes the First Coast to include the entire northeast corridor, from DC to MA, including all the premier universities and research institutions in the region.
RESI Healthtech Week’s new First Coast Innovator’s Gathering is focused on expanding the traditional Redefining Early Stage Investments (RESI) Conference to include more nascent technologies and companies in the life science space. By bringing together innovators from the entire northeast corridor with global investors and strategic partners, LSN promotes a one-of-a-kind opportunity for the advancement of healthcare innovation.
Who are the best-fit attendees?
Day 1 will feature the next generation of healthcare innovation and their earliest stage companies from the northeast region: DC, MD, PA, NJ, NY, RI, CT, and MA—now known as First Coast, who are invited to participate in a day of partnering and networking.
Qualifying First Coast Day 1 registrants are the northeast corridor incubators, accelerators, tech transfer offices, university translation initiatives, hospitals, research labs and their constituents as well as the investors and partners that seek them.
Ideal candidates include those seeing funding anywhere from $15k to $2M from grants, seed, and angel funding.
Affordability
LSN created an affordable registration price that will facilitate more startups attending the three-day event. Tickets start at only $500 for tech hubs (includes two tickets) and $300 for each additional constituent member. The pricing structure and benefits are presented in the chart below.
Showcase Your Technologies.
The conference will include ample opportunities for you to represent and showcase your technologies to global investors and strategic partners. This includes exhibiting, online features and placements, as well as a competition for a spot to pitch investors during the First Coast Innovation Challenge.
The exhibit hall has limited space for one exhibit table per tech hub (as space allows). Each organization can have up to 5 poster boards for their table to showcase their tech hub members and constituents.
In addition, all tech hubs will be featured in the RESI Healthtech Week Program Guide. Their technologies represented by their constituents and tech hub members will be featured on the newsletter and website with a datasheet.
All qualifying First Coast registrants are eligible to apply for the First Coast Innovation Challenge where the top 5 finalists will give 10-minute pitches to an elite panel of investor judges from 3:00-5:00 during the First Coast Innovator’s Gathering. This will be a rewarding opportunity to pitch your technologies and receive valuable feedback.
Access to global investors.
LSN’s network of early-stage global investors will be able to see all the key players in one place and learn about the innovative technologies coming out of the First Coast.
A day of partnering and networking.
Day 1 of the RESI Healthtech Week will feature the First Coast Innovator’s Gathering; partnering and networking opportunities, just like it’s traditional RESI.
The RESI Partnering Platform helps you find nontraditional partners from the newest sources of capital, including family offices, foundations, academic institutions, and philanthropic organizations that will be a fit for your technology and stage of development. Attendees can schedule up to 16 meetings using the Partnering Platform. It will open one month before the conference, so companies, global investors, and strategic partners can request and book meetings in advance. Some key highlights of the Partnering Platform include:
Review profiles of other RESI Conference participants.
Schedule one-on-one and/or group meetings.
Build your customized RESI Conference schedule, from panels to presentations to partnering meetings.
The system will be available one month before and one month after the conference for ease of use.
Launches August 6th for RESI Healthtech Week (September 5-6th) partnering.
In addition to the Partnering Platform, attendees can also participate in ad hoc meetings at exhibit tables and poster boards throughout the day.
Venue Information
The First Coast Innovator’s Gathering will take place at the Boston Marriott Copley Place, 110 Huntington Ave, Boston, MA 02116, on September 5th, 2018 followed by the traditional Redefining Early Stage Investments Conference on September 6th, and the Entrepreneur’s Academy Workshop Series on September 7th.
Registration starts at 7 AM. Exhibit halls and meetings are available from 8 AM to 5 PM.
In conclusion…
Life Science Nation will continue to connect early-stage companies with global investors and strategic partners through RESI Conferences and first-in-class data platforms, in the hope that downstream we can help bring treatments to the patients that need them. As the landscape for healthcare and healthcare policy changes, so too will LSN in order to meet the needs of the early-stage players.
A healthcare-focused venture capital firm based in Taiwan is investing from its new fund that is set to close in Q3 2017. The firm seeks to lead or co-invest in Pre-A to Series A rounds. Typical allocation size ranges from US$500 K to 1 million. The firm is looking for companies across the world with a focus on North America and Europe.
The firm is most interested in therapeutic projects, especially in the CNS space. The firm prefers assets with preclinical or early clinical validation. The firm is open to all modalities. The firm also considers medical devices and diagnostic technologies.
The firm is looking for experienced teams and typically requests board representation post-investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
RESI is a venue where early stage life science startups can meet with investors of every type that are a fit for their company’s technology and stage – and that includes family offices. RESI San Diego features two panels devoted to this elusive investor class – Biotech Family Offices and Medtech Family Offices. Whether you’re developing a novel therapeutic, an innovative device or an improved diagnostic solution, Family Offices can’t be overlooked as a potential source of capital and RESI will provide you with the opportunity to hear advice and insight directly from key investment decision makers from family offices.
RESI Partnering goes live on Monday, enabling fundraising life science executives and the investors who fund them to request meetings with one another on the basis of mutual fit. By getting into the system on day one you have the opportunity of being the first to request meetings, thus increasing your chances of being considered and getting the best meetings possible.
Powered by LSN’s proprietary investor data, the RESI partnering platform offers you something no other conference provider can, qualified forward-looking data on what investors are looking for. This data is one of several ingredients in RESI’s secret sauce that enables us to make so many meaningful connections (over 1500 per event!) between fundraising executives and investors.
Just getting in early isn’t enough to secure the most meaningful meetings as possible. We have been studying our partnering analytics since RESI 1, and after 12 RESI events we have proved that….big surprise….the more meeting requests you send out, the more meetings you will secure. The chart below shows the relationship between requests sent and meetings confirmed at a previous RESI event. Science and data minded folks, see for yourself!
And if all that isn’t enough to get you sign up, note that if you sign up by Friday May 19th you can beat the $200 price increase. I hope to see you all buzzing in the partnering hall in San Diego this June 19th.
In San Diego on June 19th, the Redefining Early Stage Investments (RESI) Conference will bring a new, early stage focused discussion venue for startups and investors who are visiting BIO week and want more opportunities to connect. What makes RESI different? At our last event, RESI on MaRS in Toronto, we asked our key stakeholders this question and here’s what they told us.
Ying Tam – Head of Digital Health – MaRS Discovery District
“All the research says that one of the critical elements for an entrepreneur ecosystem, especially in health, is funding and investment. It takes a long time to nurture a health company, to get it to market and commercialization and scale. So, investment is critical for the development of a startup in health. RESI brings in a whole set of investors from across North America and across the world.”
Rebecca Yu – Head of JLABS @ Toronto – Johnson & Johnson Innovation JLABS
“RESI attracts many repeat attendees, and that speaks to me that there’s a story, there’s something here. There’s great stuff happening here for entrepreneurs. There’s early stage companies from across Canada, from pharmaceuticals to medical devices to consumer health, and of course there’s a big digital health and AI presence here in Toronto. That’s why JLABS and J&J are here. We play in all the sectors, we partner with different groups within this ecosystem, and we see LSN/RESI as a key partner as well, to bring investors to this ecosystem.”
Richard Soll – Senior Vice President, International Discovery Service Unit – WuXi AppTec
“The RESI conference is an opportunity to help out these early stage companies such that they can achieve inflection points. If I can identify companies early, then I might become a vendor of choice for them. Getting in early becomes an important objective for me. When I come to a conference like RESI, I come to these early stage companies who are really looking for partnering with investors here, but also get an opportunity to introduce WuXi to them as well.”
RESI attendees can book up to 16 meetings with investors in one day, right at the start of BIO Week. If you want to take this opportunity to start your BIO with a bang, register now.
As RESI gears up for its second landing on MaRs in Toronto this April 4th we are proud to announce our latest batch of life science/health tech companies that will be participating in the RESI Innovation Challenge.
30 companies from across North America, hand selected by LSN’s scientific and commercial review team, will compete directly on merits of innovation and commercial viability. Past RESI events have seen as many as 50% of innovation challenge contestants go on to receive funding or significant partnerships within a year from the competition.
From companies helping to detect oncoming seizures to those developing cost effective ways of growing blood stem cells, this diverse class of competitors is sure to impress. Come check them our yourself in the Exhibition Hall at RESI on MaRs on April 4th!
The firm is focused on therapeutics companies and does not invest in medical devices, diagnostics, or digital health. The firm is open to considering assets of very early stages, even those as early as lead optimization phase. The firm considers various modalities, including antibodies, small molecules, and cell therapy. Currently, the firm is not interested in gene therapy. Indication-wise, the firm is most interested in oncology and autoimmune diseases but has recently looked at fibrotic diseases and certain rare diseases as well.
The firm is opportunistic across all subsectors of healthcare. Within MedTech, the firm is most interested in medical devices, artificial intelligence, robotics, and mobile health. The firm is seeking post-prototype innovations that are FDA cleared or are close to receiving clearance. Within therapeutics, the firm is interested in therapeutics for large disease markets such as oncology, neurology, and metabolic diseases. The firm is open to all modalities with a special interest in immunotherapy and cell therapy.
A strategic investment firm of a large global pharmaceutical makes investments ranging from $5 million to $30 million, acting either as a sole investor or within a syndicate. The firm is open to considering therapeutic opportunities globally, but only if the company is pursuing a market opportunity in the USA and is in dialogue with the US FDA.
The firm is currently looking for new investment opportunities in enterprise software, medical devices, and the healthcare IT space. The firm will invest in 510k devices and healthcare IT companies, and it is very opportunistic in terms of indications. In the past, the firm was active in medical device companies developing dental devices, endovascular innovation devices, and women’s health devices.
A venture capital firm founded in 2005 has multiple offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […]
Ying Tam – Head of Digital Health – MaRS Discovery District
Rebecca Yu – Head of JLABS @ Toronto – Johnson & Johnson Innovation JLABS
Richard Soll – Senior Vice President, International Discovery Service Unit – WuXi AppTec
Next Phase Newsletter 